[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599524":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":45,"collaborators":18,"id":47,"slug":18,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":18,"enrollmentInfo":56,"targetDuration":18,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":70,"overallStatus":32,"whyStopped":18,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Centre Hospitalier Régional d'Orléans","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Participants receiving vaccines and\u002For monoclonal antibodies","Participants receive standard-of-care SARS-CoV-2 and\u002For MPXV vaccines or monoclonal antibodies. This study does not assign the treatment but collects biosamples to assess antibody response.",[12],"Other: Sample collection (blood and optional nasal swab)",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"Sample collection (blood and optional nasal swab)","Venous blood collection (2 tubes of 6 mL) and optional nasal swab at each visit. Aliquots analyzed for neutralizing activity against SARS-CoV-2 and MPXV using validated assays at Institut Pasteur",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Thierry PRAZUCK, Dr","CHU Orléans","PRINCIPAL_INVESTIGATOR",[25],{"name":21,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","0238229593","+33","thierry.prazuck@chu-orleans.fr",[31],{"facility":22,"status":32,"city":33,"state":18,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Orléans","45067","France",{"type":37,"coordinates":38},"Point",[39,40],1.90407,47.90248,{"lat":40,"lon":39},[43,44],{"name":21,"role":26,"phone":27,"phoneExt":28,"email":29},{"name":21,"role":23,"phone":18,"phoneExt":18,"email":18},{"type":46,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100599524",false,"NCT07085611","Neutralizing Power of Serum Antibodies - 2","Study of the Neutralizing Power of Serum Antibodies - 2 (PNAS-2)","PNAS-2","Inclusion Criteria:\n\n* Adults (≥18 years)\n* Patients receiving or scheduled to receive anti-SARS-CoV-2 and\u002For anti-MPXV vaccines or monoclonal antibodies\n* Patients have provided written informed consent\n\nExclusion Criteria:\n\n* Persons under guardianship or curatorship\n* Persons under legal protection,\n* Persons persons deprived of liberty\n* Persons not affiliated to a social security scheme\n* Pregnant or breastfeeding women","ALL","18 Years",{"count":57,"type":58},30,"ESTIMATED","INTERVENTIONAL",[61],"NA","Severe forms of COVID-19 and Monkeypox affect immunocompromised and comorbid individuals. Vaccination and monoclonal antibody therapies induce neutralizing antibodies. This neutralizing power is recognized as a correlate of protection against a new infection. This study aims to describe the neutralizing power of serum and nasal antibodies over time, in relation to SARS-CoV-2 and MPXV vaccines or treatments received.",[64,65,66,67,68,69],"COVID-19","SARS-CoV-2 Viraemia","Monkey Pox","Vaccination","Serum","Mucosal Immunity",[71,72,73,67,68,74],"Neutralizing antibodies","SARS-CoV-2","Monkeypox","Mucosal immunity","2025-12-12",{"date":77,"type":78},"2025-12-19","ACTUAL",{"date":80,"type":78},"2025-08-22",{"date":82,"type":58},"2035-07-11",{"name":5,"class":6},1]